COMMUNIQUÉS West-GlobeNewswire

Elsalys Biotech : LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD
05/04/2018
LEUKOTAC® takes next step in paediatric acute steroid-resistant GvHD ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to conduct a [...]
Elsalys Biotech : LEUKOTAC, les prochaines étapes dans la GvHD aigüe et cortico-résistante en pédiatrie
05/04/2018
LEUKOTAC ® , les prochaines étapes dans la GvHD aigüe et cortico-résistante en pédiatrie ELSALYS BIOTECH prévoit de déposer avant l'été 2018 un plan d'investigation pédiatrique (PIP) auprès de l'Agence Européenne du [...]
Shire plc : Rule 2.9 Announcement
05/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 5 April 2018 Shire [...]
OSE Immunotherapeutics to Host Conference Call on April 5, 2018 to Discuss Boehringer Ingelheim Global Immuno-Oncology Partnership
05/04/2018
NANTES, France, April 05, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announced that it will host an audio/web conference to discuss its global immuno-oncology partnership [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
05/04/2018
REGULATED INFORMATION GHENT, Belgium, 5 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
05/04/2018
REGULATED INFORMATION GHENT, Belgium, 5 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy
05/04/2018
Pratteln, Switzerland, April 5, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports the successful completion of the first clinical trial with omigapil in patients with two forms of congenital muscular dystrophy (CMD) [...]
Biocartis Group NV: Biocartis announces publication of its 2017 annual report
05/04/2018
PRESS RELEASE : REGULATED INFORMATION 5 April 2018, 07:00 CEST Biocartis announces publication of its 2017 annual report Mechelen, Belgium, 5 April 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
Mesa Labs Declares Quarterly Dividend
05/04/2018
Lakewood, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- – Mesa Laboratories, Inc. (NASDAQ: MLAB ) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend [...]
CORRECTING and REPLACING - Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
05/04/2018
In a release issued under the same headline earlier today by Precision Therapeautics (NASDAQ: AIPT ), please note that the forward-looking statements paragraph was missing. The corrected release follows: MINNEAPOLIS, [...]
Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18
04/04/2018
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that it will present at the H.C. Wainwright Global Lifesciences conference on 04/09/18 at 4:15 PM [...]
Align Technology Extends Invisalign G5 Precision Bite Ramps to Vivera Retainers
04/04/2018
First Customizable Retainers Designed to Help Preserve Beautiful Smiles After Deep Bite Correction with Invisalign Treatment SAN JOSE, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN ) [...]
Align Technology Introduces Invisalign Clear Aligners for Phase 1 Treatment of Younger Patients With Early Mixed Dentition
04/04/2018
Invisalign® First Increases Invisalign Applicability to 70 Percent of Annual Orthodontic Case Starts Worldwide SAN JOSE, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN ) today announced [...]
Align Technology Expands Invisalign® Product Portfolio With New Options and Greater Flexibility to Treat a Broader Range of Patients
04/04/2018
Creates New Invisalign Treatment Packages to Give Doctors More Choices Extends Popular Teen Features Across the Invisalign Portfolio Launches Clear Aligner Product for Phase 1 Treatment of Young Patients SAN JOSE, Calif [...]
T2 Biosystems Reports Granting of Inducement Awards
04/04/2018
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in [...]
Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
04/04/2018
Biopsy-based Proof of Concept in Liver Fibrosis and Cirrhosis Supports Further Evaluation Conference Call and Webcast Presentation at 4:30 p.m. ET Today SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Conatus [...]
Immunovaccine Files Circular for Annual and Special Meeting of Shareholders
04/04/2018
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 04, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology [...]
Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering and Concurrent $92 Million Private Placement of Common Stock
04/04/2018
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
04/04/2018
-- PDUFA Action Date in October 2018 -- BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug [...]

Pages